OS Therapies Raises $2 Million via Convertible Notes

OS Therapies Incorporated ( (OSTX) ) just unveiled an announcement.

On March 4, 2026, OS Therapies Incorporated raised $2 million in gross proceeds through a private placement of 10% original issue discount unsecured convertible promissory notes with an aggregate principal of $2.2 million and accompanying warrants to purchase up to 1,666,667 common shares. After paying a 7% cash fee and expense reimbursement to its placement agent, the company earmarked net proceeds to fund clinical development activities, R&D programs, and general corporate needs, while agreeing to restrictions on variable-price equity issuance and to register the underlying shares for resale.

The notes bear 4% annual interest and mature on March 4, 2027, with mandatory conversion into securities upon a future qualified registered offering of at least $2.5 million, and optional conversion at a 10% discount to the recent volume-weighted average price, subject to ownership caps and a 19.99% issuance limit without shareholder approval. The five-year warrants, exercisable immediately at $1.40 per share with anti-dilution adjustments and forced exercise provisions, add potential future dilution but also align investors with upside in the company’s stock, while negative covenants on additional debt, dividends, and affiliate transactions seek to protect noteholders and constrain OS Therapies’ capital-structure flexibility.

The most recent analyst rating on (OSTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.

Spark’s Take on OSTX Stock

According to Spark, TipRanks’ AI Analyst, OSTX is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, and continued cash burn) and negative-to-neutral technical momentum (below key moving averages with negative MACD). A recent capital raise that reportedly extends runway into 2027 helps mitigate near-term liquidity risk, but valuation remains constrained by ongoing losses and the lack of a dividend.

To see Spark’s full report on OSTX stock, click here.

More about OS Therapies Incorporated

OS Therapies Incorporated operates in the biopharmaceutical sector, focusing on clinical development and research and development programs, including ongoing and planned clinical trials. The company directs its capital toward advancing therapeutic candidates and supporting working capital and other general corporate purposes tied to its pipeline.

Average Trading Volume: 549,290

Technical Sentiment Signal: Sell

Current Market Cap: $53.17M

Find detailed analytics on OSTX stock on TipRanks’ Stock Analysis page.